Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESKUE: FBX-101 Gene Therapy in Infantile Krabbe Disease with HSCT
2023-504900-28-00Phase 2Withdrawn
- Sponsor
- Forge Biologics
- Start
- Aug 2023
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of FBX-101 in Krabbe disease, sponsored by Forge Biologics. Primary endpoints: Incidence and severity of adverse events and serious adverse events attributed to FBX-101 and HSCT incident of engraftment. Planned start Aug 2023; status: withdrawn.
02
Drugs
FBX-101
03
Conditions
Krabbe disease
Beyond the preview
Go deeper on 2023-504900-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504900-28-00.